Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation

Although insulin-like growth factor 2 (IGF2) has been reported to be overexpressed in steatosis and steatohepatitis, a causal role of IGF2 in steatosis development remains elusive. Aim of our study was to decipher the role of IGF2 in steatosis development.Hydrodynamic gene delivery of the Igf2 plasm...

Full description

Bibliographic Details
Main Authors: Sonja M Kessler, Stephan eLaggai, Elien evan Wonterghem, Katja eGemperlein, Rolf eMüller, Johannes eHaybaeck, Roosmarijn E Vandenbroucke, Manfred eOgris, Claude eLibert, Alexandra K Kiemer
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-04-01
Series:Frontiers in Physiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00147/full
id doaj-ebe9f798b3584fe5a8a53adbcd4e7fd2
record_format Article
spelling doaj-ebe9f798b3584fe5a8a53adbcd4e7fd22020-11-24T21:40:57ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2016-04-01710.3389/fphys.2016.00147173920Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formationSonja M Kessler0Stephan eLaggai1Elien evan Wonterghem2Elien evan Wonterghem3Katja eGemperlein4Rolf eMüller5Johannes eHaybaeck6Roosmarijn E Vandenbroucke7Roosmarijn E Vandenbroucke8Manfred eOgris9Claude eLibert10Claude eLibert11Alexandra K Kiemer12Saarland UniversitySaarland UniversityVIBGhent UniversityHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology (HZI)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology (HZI)Medical University of GrazVIBGhent UniversityUniversity of ViennaVIBGhent UniversitySaarland UniversityAlthough insulin-like growth factor 2 (IGF2) has been reported to be overexpressed in steatosis and steatohepatitis, a causal role of IGF2 in steatosis development remains elusive. Aim of our study was to decipher the role of IGF2 in steatosis development.Hydrodynamic gene delivery of the Igf2 plasmid used for transient IGF2 overexpression employing codon-optimized plasmid DNA resulted in a strong induction of hepatic Igf2 expression. The exogenously delivered Igf2 had no influence on endogenous Igf2 expression. The downstream kinase AKT was activated in IGF2 animals. Decreased ALT levels mirrored the cytoprotective effect of IGF2. Serum cholesterol was increased and sulfo-phospho-vanillin colorimetric assay confirmed lipid accumulation in IGF2-livers without signs of inflammation. Interestingly, hepatic cholesterol and phospholipids, determined by thin layer chromatography and free cholesterol by filipin staining, were specifically increased. Lipid droplet (LD) size was not changed, but their number was significantly elevated. Furthermore, free cholesterol, which can be stored in LDs and has been reported to be critical for steatosis progression, was elevated in IGF2 overexpressing mice. Accordingly, HmgCoAR was upregulated. To have a closer look at de novo lipid synthesis we investigated expression of the lipogenic transcription factor SREBP1 and its target genes. SREBP1 was induced and also SREBP1 target genes were slightly upregulated. Interestingly, the expression of Cpt1a, which is responsible for mitochondrial fatty acid oxidation, was induced. Hepatic Igf2 expression induces a fatty liver, characterized by increased cholesterol and phospholipids leading to accumulation of LDs. We therefore suggest a causal role for IGF2 in hepatic lipid accumulation.http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00147/fullFatty LiverIGF-1lipid dropletsNAFLDInsulin-like growth factor 2 (Igf2)NASH
collection DOAJ
language English
format Article
sources DOAJ
author Sonja M Kessler
Stephan eLaggai
Elien evan Wonterghem
Elien evan Wonterghem
Katja eGemperlein
Rolf eMüller
Johannes eHaybaeck
Roosmarijn E Vandenbroucke
Roosmarijn E Vandenbroucke
Manfred eOgris
Claude eLibert
Claude eLibert
Alexandra K Kiemer
spellingShingle Sonja M Kessler
Stephan eLaggai
Elien evan Wonterghem
Elien evan Wonterghem
Katja eGemperlein
Rolf eMüller
Johannes eHaybaeck
Roosmarijn E Vandenbroucke
Roosmarijn E Vandenbroucke
Manfred eOgris
Claude eLibert
Claude eLibert
Alexandra K Kiemer
Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
Frontiers in Physiology
Fatty Liver
IGF-1
lipid droplets
NAFLD
Insulin-like growth factor 2 (Igf2)
NASH
author_facet Sonja M Kessler
Stephan eLaggai
Elien evan Wonterghem
Elien evan Wonterghem
Katja eGemperlein
Rolf eMüller
Johannes eHaybaeck
Roosmarijn E Vandenbroucke
Roosmarijn E Vandenbroucke
Manfred eOgris
Claude eLibert
Claude eLibert
Alexandra K Kiemer
author_sort Sonja M Kessler
title Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
title_short Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
title_full Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
title_fullStr Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
title_full_unstemmed Transient hepatic overexpression of Insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
title_sort transient hepatic overexpression of insulin-like growth factor 2 induces free cholesterol and lipid droplet formation
publisher Frontiers Media S.A.
series Frontiers in Physiology
issn 1664-042X
publishDate 2016-04-01
description Although insulin-like growth factor 2 (IGF2) has been reported to be overexpressed in steatosis and steatohepatitis, a causal role of IGF2 in steatosis development remains elusive. Aim of our study was to decipher the role of IGF2 in steatosis development.Hydrodynamic gene delivery of the Igf2 plasmid used for transient IGF2 overexpression employing codon-optimized plasmid DNA resulted in a strong induction of hepatic Igf2 expression. The exogenously delivered Igf2 had no influence on endogenous Igf2 expression. The downstream kinase AKT was activated in IGF2 animals. Decreased ALT levels mirrored the cytoprotective effect of IGF2. Serum cholesterol was increased and sulfo-phospho-vanillin colorimetric assay confirmed lipid accumulation in IGF2-livers without signs of inflammation. Interestingly, hepatic cholesterol and phospholipids, determined by thin layer chromatography and free cholesterol by filipin staining, were specifically increased. Lipid droplet (LD) size was not changed, but their number was significantly elevated. Furthermore, free cholesterol, which can be stored in LDs and has been reported to be critical for steatosis progression, was elevated in IGF2 overexpressing mice. Accordingly, HmgCoAR was upregulated. To have a closer look at de novo lipid synthesis we investigated expression of the lipogenic transcription factor SREBP1 and its target genes. SREBP1 was induced and also SREBP1 target genes were slightly upregulated. Interestingly, the expression of Cpt1a, which is responsible for mitochondrial fatty acid oxidation, was induced. Hepatic Igf2 expression induces a fatty liver, characterized by increased cholesterol and phospholipids leading to accumulation of LDs. We therefore suggest a causal role for IGF2 in hepatic lipid accumulation.
topic Fatty Liver
IGF-1
lipid droplets
NAFLD
Insulin-like growth factor 2 (Igf2)
NASH
url http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00147/full
work_keys_str_mv AT sonjamkessler transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT stephanelaggai transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT elienevanwonterghem transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT elienevanwonterghem transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT katjaegemperlein transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT rolfemuller transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT johannesehaybaeck transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT roosmarijnevandenbroucke transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT roosmarijnevandenbroucke transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT manfredeogris transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT claudeelibert transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT claudeelibert transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
AT alexandrakkiemer transienthepaticoverexpressionofinsulinlikegrowthfactor2inducesfreecholesterolandlipiddropletformation
_version_ 1725923765264580608